A carregar...
A Comprehensive Review of Pacritinib in Myelofibrosis
The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable reductions in splenomegaly and constitutional symptoms in patients with myelofibrosis. However, the association of ruxolitinib therapy with myelosuppression indicates the continued need for optimal treat...
Na minha lista:
| Publicado no: | Future Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918816/ https://ncbi.nlm.nih.gov/pubmed/26367195 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.15.200 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|